Aprea Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	41.23	14.6	22.85	21.61	28.79	53.08
Cash & Short-Term Investments	41.23	14.6	22.85	21.61	28.79	53.08
Cash Growth	149.41%	-36.11%	5.75%	-24.94%	-45.76%	-
Prepaid Expenses	0.68	0.96	0.73	0.91	1.37	3.51
Total Current Assets	41.91	15.56	23.58	22.52	30.15	56.58
Property, Plant & Equipment	0.06	0.06	0.08	0.09	0	0.21
Other Long-Term Assets	0.31	0.31	0.32	0.04	-	0.03
Total Assets	42.29	15.93	23.98	22.65	30.16	56.82
Accounts Payable	0.94	0.71	1.35	1.67	0.84	1.77
Accrued Expenses	2.16	2.05	2.01	2.19	2.36	5.35
Current Portion of Leases	-	-	-	-	-	0.19
Current Unearned Revenue	-	-	-	0.53	-	-
Total Current Liabilities	3.09	2.76	3.36	4.39	3.2	7.32
Total Liabilities	3.09	2.76	3.36	4.39	3.2	7.32
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	389.6	356.71	350.97	335.64	330.06	241
Retained Earnings	-340.52	-333.64	-321.04	-308.08	-293.8	-181.13
Comprehensive Income & Other	-10.62	-10.63	-10.63	-10.61	-10.62	-10.36
Total Common Equity	38.47	12.44	19.31	16.95	25.64	49.51
Shareholders' Equity	39.2	13.17	20.62	18.26	26.95	49.51
Total Liabilities & Equity	42.29	15.93	23.98	22.65	30.16	56.82
Total Debt	-	-	-	-	-	0.19
Net Cash (Debt)	41.23	14.6	22.85	21.61	28.79	52.89
Net Cash Growth	149.41%	-36.11%	5.75%	-24.94%	-45.57%	-
Net Cash Per Share	2.00	2.23	4.15	5.97	17.37	49.69
Filing Date Shares Outstanding	12.59	11.45	5.49	5.43	3.73	1.06
Total Common Shares Outstanding	12.39	8.19	5.48	3.74	2.66	1.06
Working Capital	38.82	12.8	20.22	18.14	26.95	49.27
Book Value Per Share	3.10	1.52	3.52	4.54	9.66	45.97
Tangible Book Value	38.47	12.44	19.31	16.95	25.64	49.51
Tangible Book Value Per Share	3.10	1.52	3.52	4.54	9.66	45.97
Machinery	-	0.15	0.15	0.14	0.05	0.14

SEC Filings: 10-K · 10-Q